Indian firms linked to cough syrup deaths received warnings

Published September 14, 2023
People stand outside the Maiden Pharmaceuticals plant that was sealed by the Indian government officials in 2022, in Sonipat in the northern state of Haryana, India, February 2, 2023. — Reuters
People stand outside the Maiden Pharmaceuticals plant that was sealed by the Indian government officials in 2022, in Sonipat in the northern state of Haryana, India, February 2, 2023. — Reuters

NEW DELHI: The deaths of 12 children in northern India between December 2019 and January 2020, police allege, were caused by adulterated cough syrup made by drugmaker Digital Vision. It was not the first time the company’s medicines have come under scrutiny.

Indian drugs regulators found quality shortfalls in drugs made by Digital and its unit Orison Pharmaceuticals at least 22 times between 2012 and July this year, according to this news agency review of records from five states and India’s federal drugs regulator CDSCO.

The medicines either did not contain the claimed volume of ingredients or failed to dissolve quickly enough for absorption by the body, according to the records.

Digital Vision founder Parshottam Goyal downplayed the shortfalls. “Drug samples of every company fail on some criteria every now and then: small mismatches in the quantity of medicines and things like that,” he said, when asked about the regulators’ warnings.

Tests by government laboratories in 2020 found that a batch of Digital Vision’s COLDBEST-PC cough syrup taken by the children in the northern region of Jammu and Kashmir contained high levels of toxic chemicals. The company has denied this and said its syrup was not to blame for the wave of poisonings, without providing proof.

Maiden Pharmaceuticals — whose cough syrups have been linked to deaths of at least 70 children in Gambia last year had also been alerted by regulators to quality shortfalls in some of its drugs.

Regulators found at least 10 medicines produced in India by Maiden were “not of standard quality,” according to records shared by India’s Department of Pharmaceuticals with parliament in March. The eastern state of Bihar in 2011 banned the company for five years for selling substandard medicines there.

India’s health ministry and the CDSCO did not respond to requests for comment.

Maiden, which has denied its cough syrup was responsible for the deaths in Gambia.

When Maiden produced the syrups exported to Gambia in late 2021, its founder, Naresh Kumar Goyal, and Technical Director Mahender Kumar Sharma were already on bail since March 2018 in a separate case on charges of illegally storing substandard medicines, according to documents from a court in Haryana state.

Goyal did not respond to requests for comment; Sharma could not be reached.

The court documents show that inspectors visited Maiden’s factory in 2014 after Vietnam had banned the company the previous year for allegedly selling another heartburn drug there that did not meet specifications.

Maiden’s lawyers told the court in Haryana its own testing had shown the drugs discovered by the Indian inspectors fell short and it had not intended to sell them.

Published in Dawn, September 14th, 2023

Opinion

Editorial

Time for dialogue
Updated 24 Jun, 2024

Time for dialogue

If the PML-N and PTI remain mired in mutual acrimony, an ever-widening gap will continue to allow non-political forces to assert themselves.
Property taxes
24 Jun, 2024

Property taxes

ACCORDING to reports in the local media, along with the higher taxes imposed on real estate in the recent budget, ...
Fierce heat
24 Jun, 2024

Fierce heat

CLIMATE change is unfolding as predicted by experts: savage heat, melting glaciers, extreme rainfall, drought, ...
China’s concerns
23 Jun, 2024

China’s concerns

Pakistan has no option but to neutralise militant threat to Chinese projects, as well as address its business and political stability concerns.
War drums
23 Jun, 2024

War drums

If it is foolish enough to launch another war in Lebanon, Tel Aviv will be solely responsible for setting the Middle East on fire.
Balochistan budget
23 Jun, 2024

Balochistan budget

BALOCHISTAN’S Rs955.6bn budget for the fiscal year 2024-25 makes many pledges to the poor citizens of Pakistan’s...